Abstract：【Objective】 To investigate the clinicopathological characteristics of patients with BRAF V600E mutant gastrointestinal stromal tumors (GISTs) and their impact on prognosis. 【Methods】 A retrospective analysis was conducted on the clinical data of 58 patients with BRAF V600E mutant GISTs (mutation group) and 92 patients with BRAF wild-type GISTs (wild-type group). Clinicopathological features and survival outcomes were compared between the two groups. Univariate analysis and Cox proportional hazards regression models were used to identify independent prognostic factors for GIST. 【Results】 Compared with the wild-type group, the mutation group had a higher proportion of patients aged ≥55 years, tumors larger than 5 cm, and advanced TNM stage (stage Ⅲ+Ⅳ) (all P<0.05). Survival analysis showed that the mean overall survival (OS) and disease-free survival (DFS) in the mutation group were significantly shorter than those in the wild-type group (P<0.05). Univariate Cox regression analysis indicated that age, tumor size, TNM stage, and BRAF V600E mutation were adverse prognostic factors for GIST. Multivariate Cox regression analysis further demonstrated that age, tumor size, TNM stage, and BRAF V600E mutation were independent risk factors for poor prognosis in GIST. 【Conclusion】 Patients with BRAF V600E mutant GISTs exhibit poorer clinicopathological features and prognosis. Age, tumor size, TNM stage, and BRAF V600E mutation are independent prognostic risk factors for GIST.
2026, Vol. 43 
